- Home
- ABVC vs TENX Comparison
ABVC vs TENX Comparison
Compare ABVC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- TENX
- Stock Information
- Founded
- ABVC 2015
- TENX 1967
- Country
- ABVC United States
- TENX United States
- Employees
- ABVC N/A
- TENX N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- TENX Health Care
- Exchange
- ABVC Nasdaq
- TENX Nasdaq
- Market Cap
- ABVC 22.1M
- TENX 21.6M
- IPO Year
- ABVC N/A
- TENX N/A
- Fundamental
- Price
- ABVC $2.19
- TENX $5.93
- Analyst Decision
- ABVC
- TENX Strong Buy
- Analyst Count
- ABVC 0
- TENX 3
- Target Price
- ABVC N/A
- TENX $16.00
- AVG Volume (30 Days)
- ABVC 312.1K
- TENX 35.4K
- Earning Date
- ABVC 08-13-2025
- TENX 08-12-2025
- Dividend Yield
- ABVC N/A
- TENX N/A
- EPS Growth
- ABVC N/A
- TENX N/A
- EPS
- ABVC N/A
- TENX N/A
- Revenue
- ABVC $508,383.00
- TENX N/A
- Revenue This Year
- ABVC $735.18
- TENX N/A
- Revenue Next Year
- ABVC N/A
- TENX N/A
- P/E Ratio
- ABVC N/A
- TENX N/A
- Revenue Growth
- ABVC 1904.43
- TENX N/A
- 52 Week Low
- ABVC $0.40
- TENX $2.80
- 52 Week High
- ABVC $2.29
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- ABVC 70.75
- TENX 51.83
- Support Level
- ABVC $1.84
- TENX $5.62
- Resistance Level
- ABVC $2.29
- TENX $6.35
- Average True Range (ATR)
- ABVC 0.16
- TENX 0.46
- MACD
- ABVC 0.03
- TENX 0.01
- Stochastic Oscillator
- ABVC 87.65
- TENX 41.49
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.